In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study-Reference-Cited by-同舟云学术

In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study

Published:2017-03-22 Issue:26 Volume:8 Page:43458-43469
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Mai Haixing¹,Huang Jun¹,Zhang Yuanyuan²,Qu Nang¹,Qu Hengyan¹,Mei Guo-hui¹,Liu Jiannan¹,Xu Xiaojie³,Chen Lijun¹

Affiliation:

1. Department of Urology, 307 Hospital, Affiliated Hospital of Military Medical Sciences, Beijing, China

2. Department of Clinical Pharmacology, 307 Hospital, Affiliated Hospital of Military Medical Science Academy of the PLA, Beijing, China

3. Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Beijing, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma;Clinical Genitourinary Cancer;2024-06

2. Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells;Lab on a Chip;2024

3. Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats;Molecules;2022-08-24

4. Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles;Journal of Colloid and Interface Science;2022-02

5. Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism;Science Advances;2022-01-21